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Background: In patients with chronic kidney disease (CKD) hyperuricemia is common. Evidence that hyperuricemia
might also play a causal role in vascular disease, hypertension and progression of CKD is accumulating. Therefore,
we studied the association between baseline uric acid (UA) levels and the rate of decline in renal function and time
until start of dialysis in pre-dialysis patients.
Methods: Data from the PREPARE-2 study were used. The PREPARE-2 study is an observational prospective cohort
study including incident pre-dialysis patients with CKD stages IV-V in the years between 2004 and 2011. Patients were
followed for a median of 14.9 months until start of dialysis, kidney transplantation, death, or censoring. Main outcomes
were the change in the rate of decline in renal function (measured as estimated glomerular filtration rate (eGFR))
estimated using linear mixed models, and time until start of dialysis estimated using Cox proportional hazards models.
Results: In this analysis 131 patients were included with a baseline UA level (mean (standard deviation (SD)) of
8.0 (1.79) mg/dl) and a mean decline in renal function of −1.61 (95% confidence interval (CI), −2.01; −1.22) ml/min/
1.73 m2/year. The change in decline in GFR associated with a unit increase in UA at baseline was −0.14 (95%
CI −0.61;0.33, p = 0.55) ml/min/1.73 m2/year. Adjusted for demography, comorbidities, diet, body mass index
(BMI), blood pressure, lipids, proteinuria, diuretic and/or allopurinol usage the change in decline in eGFR did not
change. The hazard ratio (HR) for starting dialysis for each mg/dl increase in UA at baseline was 1.08 (95% CI, 0.94;1.24,
p = 0.27). After adjustment for the same confounders the HR became significant at 1.26 (95% CI, 1.06;1.49, p = 0.01),
indicating an earlier start of dialysis with higher levels of UA.
Conclusion: Although high UA levels are not associated with an accelerated decline in renal function, a high serum
UA level in incident pre-dialysis patient is a risk factor for an earlier start of dialysis.
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Uric acid (UA) is an emerging risk factor for renal disease,
hypertension, and cardiovascular disease. Hyperuricemia
is common in patients with chronic kidney disease (CKD)
and evidence that hyperuricemia may also play a causal
role in hypertension, vascular disease and progression of
CKD is accumulating [1-9]. In addition, some intervention
studies have shown that treatment of hyperuricemia could* Correspondence: h.nacak@lumc.nl
1Department of Clinical Epidemiology, Leiden University Medical Center,
Albinusdreef 2, Leiden 2333 ZA, The Netherlands
Full list of author information is available at the end of the article
© 2014 Nacak et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.be beneficial for blood pressure regulation and preserva-
tion of kidney function [10,11]. Therefore, screening for
hyperuricemia in CKD patients might help to identify
patients that have an accelerated decline in renal function
and thereby an increased risk for progression to ESRD.
The association between UA and decline in renal func-
tion has been investigated in several studies which included
healthy individuals [12,13], patients with CKD stages I-II
[14,15], patients with diabetes [6], and patients on periton-
eal dialysis [16]. However, evidence about this associationtd. This is an Open Access article distributed under the terms of the Creative
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the effect on time until start of dialysis has not been
addressed specifically.
The aim of our study is to investigate the association
between baseline UA levels and the annual rate of
decline in renal function and time until start of dialysis
in CKD stage IV-V patients referred to specialized pre-
dialysis care. We hypothesize that UA in these patients
is associated with accelerated decline in renal function
and an earlier start of dialysis.
Methods
Study design
The association between UA and the annual rate of
decline in renal function and time until start of dialysis
was investigated in the ongoing PRE-dialysis PAtient
REcord-2 (PREPARE-2) study, an observational pro-
spective cohort study in incident pre-dialysis care pa-
tients. These patients were recruited from 25 nephrology
outpatient clinics in the Netherlands. They were regularly
seen by their nephrologist and treated in accordance with
the treatment guidelines of the Dutch Federation of
Nephrology, which are partly based on the K/DOQI
and EBPG guidelines [17-20]. Data were collected in 6-
monthly intervals from the start of pre-dialysis care
onwards. Patients were followed until start of dialysis,
kidney transplantation, death or censoring. Patients were
censored if they refused to further participate, if they
moved to an outpatient clinic not participating in the
PREPARE-2 study, if they were lost to follow-up, if their
kidney function normalized, or if their follow-up was still
continuing on February 12, 2013, whichever came first.
The medical ethics committee or institutional review
boards (when appropriate) of all participating centers ap-
proved this study (see Additional file 1: ‘Ethical approval
Prepare-2 study’).
Study population
Patients were eligible for inclusion if they were 18 years
or older and had been referred to a specialized pre-
dialysis outpatient clinic. In practice, this meant that the
included pre-dialysis patients had an estimated glomerular
filtration rate (eGFR) of less than 20–30 ml/min/1.73 m2
accompanied by a progressive decline in renal function.
Patients were also included if they had a failing transplant
and had been transplanted at least one year ago. Prior to
inclusion all patients gave written informed consent.
Measurement and definitions
In addition to the routine collection, laboratory data
were also extracted from the electronic hospital informa-
tion systems or medical records. The closest laboratory
measurement performed within 90 days before or after
the date of a visit was appointed to that visit. When noserum UA measurement was available on the first visit,
but it was measured during the second visit, then this
value was defined as the baseline value for UA. Variables
used in the multivariable analysis were determined on the
same visit as UA. Patients were regarded as hypertensive if
a physician had diagnosed them as such. Proteinuria was
defined as >300 mg/day protein in urine. The eGFR was
calculated using the 4-variable Modification of Diet in
Renal Disease (MDRD) formula, taking into account age,
sex, black race, and serum creatinine [21].
Outcomes
The main outcomes are the change in rate of decline in
renal function and time until start of dialysis per mg/dl
increase in baseline UA. To calculate the rate of decline
in renal function, all available eGFR measurements from
three months prior to inclusion until end of follow-up
were used. In patients initiating dialysis, eGFR measure-
ments until two weeks before the start of dialysis were
used, because eGFR measurements after this point in
time were no longer representative of true kidney func-
tion. Start of dialysis was defined as starting HD or PD
during follow-up.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD), skewed variables are presented as median
(boundaries of interquartile range, IQR) and categorical
variables are presented as percentages. Baseline charac-
teristics are presented for the total study population and
stratified by patients below or above the median serum
UA level at baseline.
A linear mixed model (LMM) was used to estimate
the change in the rate of decline in renal function with
each mg/dl higher UA level at baseline [22]. In contrast
to a standard linear model, the LMM takes into account
that repeated eGFR measurements of the same patient
are correlated. Multivariable analysis was used to adjust
for potential confounders and we defined two adjusted
models: age, sex, primary kidney disease, body mass index
(BMI), presence of cardiovascular disease (CVD; angina
pectoris, coronary disease, history of cerebrovascular acci-
dents, heart failure, and/or myocardial infarction), ethni-
city, hypertension, presence of diabetes mellitus (DM; type
1 and 2), protein restricted diet, systolic blood pressure
(model 1) and model 1 plus low-density lipoprotein (LDL),
cholesterol, proteinuria, diuretic use and allopurinol use
(model 2) .
Kaplan-Meier analysis was performed to produce sur-
vival plots [23]. A Cox proportional hazards analysis was
used to estimate the hazard ratio (HR) for starting
dialysis with each mg/dl higher UA level at baseline [24].
Follow-up time in this Cox proportional hazards analysis
was the time between the baseline UA measurement and
Table 1 Baseline characteristics for patients with UA
levels above and below median and all patients
UA ≤ 7.9 mg/dl UA > 7.9 mg/dl Total
(median) (median) (n = 131)
(n = 70) (n = 61)
UA (mg/dl) (sd) 6.69 (0.89) 9.5 (1.32) 8.0 (1.79)
Age (years) (sd) 64.0 (14.0) 63.2 (15.4) 63.6 (14.6)
Sex (% male) 62.9 75.4 68.7
Ethnicity (% caucasian) 94.3 98.4 96.2
Diabetes (%) 20.0 19.7 19.8
PKD
% Diabetes 7.1 9.8 8.4
% Glomerulonephritis 12.9 13.1 13.0
% Renal vascular disease 27.1 34.4 30.5
% Other 52.9 42.6 48.1
Hypertension* (%) 74.3 83.6 78.6
BMI (kg/m2) (sd) 26.3 (4.8) 25.0 (3.9) 25.7 (4.4)
CVD (%) 35.7 44.3 39.7
eGFR (MDRD)** (sd) 16.9 (5.7) 16.4 (5.7) 16.8 (5.7)
SBP (mm Hg) (sd) 143.9 (21.6) 141.4 (17.9) 142.7 (19.9)
DBP (mm Hg) (sd) 78.8 (12.3) 78.7 (10.9) 78.8 (11.6)
Total cholesterol
(mmol/L) (sd)
4.33 (0.95) 4.48 (1.0) 4.42 (0.98)
LDL (mmol/L) (sd) 2.37 (0.78) 2.52 (0.95) 2.47 (0.87)
Proteinuria*** (%) 85.7 66.7 67.7
Diuretics (%) 44.1 55.7 50.4
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loss to follow up, refusal of further participation, transfer
to another outpatient clinic that doesn’t participate in the
PREPARE-2 study and follow-up continuing until at least
February 12, 2013 were treated as censored events. The
multivariable Cox analysis was adjusted for the same
confounders as the LMM.
Missing values of potential confounders at baseline were
imputed for patients with a baseline UA value using mul-
tiple imputation with 10 repetitions. The imputed data are
predicted based on known information of each individual
[25]. Besides the variables in model 1 and 2, diastolic
blood pressure, high density lipoprotein, triglycerides,
baseline eGFR, follow-up time and the endpoint reached
(start of dialysis or not) were used for imputation. Follow-
up time was skewed and was therefore logarithmically
transformed before entering into the model.
Multiple sensitivity analyses were performed to test the
robustness of our findings. First, we repeated our two
main analyses without imputing missing confounder data.
Second, alongside the main analysis (i.e. UA on a continu-
ous scale) we dichotomized UA levels based on the
normal values for UA (i.e. 7.06 mg/dl for men and 5.72 for
women). Third, we added baseline eGFR levels to our
models, in order to adjust for potential discrepancies in
the eGFR at baseline.
P < 0.05 was considered statistically significant. All ana-
lyses were performed in PASW/SPSS version 20.0 for
Windows.Protein-restricted diet (%) 73.1 80.3 76.9
Allopurinol (%) 29.4 4.9 18.2
PKD = Primary kidney disease, BMI = Body Mass Index, CVD = Cardiovascular
disease, SBP = systolic blood pressure, DBP = diastolic blood pressure,
LDL = low-density lipoprotein.
*As diagnosed by a physician.
**in ml/min/1.73 m3.
***defined as >300 mg/day in urine.Results
Patient characteristics
In total, 502 incident pre-dialysis patients were included
in the PREPARE-2 study and prospectively followed. A
total of 131 patients had a baseline UA measurement. Pa-
tients with a UA measurement at the first visit (0 months)
did not differ from patients with a UA measurement at
the second visit (6 months) (data not shown). Baseline
characteristics for the total population and for patients
with UA levels above and below the median are shown in
Table 1. The 131 patients had a median UA level of 7.9
mg/dl at baseline, mean (SD) age was 63.6 (14.6) years
and 68.7% of the patients were male. If UA levels at base-
line were above the median UA level, patients were more
often male (75.4% versus 62.9%). They were also more
often hypertensive (83.6% vs. 74.3%), had less often pro-
teinuria (66.7% vs. 85.7%), and used more often diuretics
(55.7% vs. 44.1%). Allopurinol was used less often in pa-
tients with UA levels above the median (4.9% vs. 29.4%).
Of the 19 variables that were used to impute missing data
9 were complete and 6 variables had less than 5% missing
data. On average the percentage of missing data per con-
founder was 7.7%.Decline in renal function
The patients had on average 3.46 (1.80) measurements of
eGFR during follow-up. For 125 patients an eGFR meas-
urement was available at baseline and the mean (SD)
eGFR for these patients was 16.6 (5.7) ml/min/1.73 m2.
The mean decline in renal function was −1.61 ml/min/
1.73 m2/year (95% CI −2.01, −1.22); indicating a loss in
renal function over time.
Each mg/dl higher UA level at baseline was associ-
ated with a change in the rate of decline in renal func-
tion of −0.14 ml/min/1.73 m2/year (95% CI −0.61,0.33).
After adjustment for age, sex, ethnicity, primary kidney
disease (PKD), comorbidities (CVD, DM, hypertension),
BMI, protein restricted diet, systolic blood pressure
(model 1) each mg/dl higher UA level at baseline was asso-
ciated with a change in the rate of decline in renal function
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itional adjustment for LDL, cholesterol, proteinuria, diur-
etic use, and allopurinol use (model 2) again resulted in an
associated change in decline in renal function of −0.14 ml/
min/1.73 m2/year (95% CI −0.70,0.42) per mg/dl UA
(Table 2).
Time until start of dialysis
Seventy-one (54.2%) patients started dialysis during follow
up. Hemodialysis was modality of choice for 40 (56.3%)
patients, the remaining 31 (43.7%) patients started with
peritoneal dialysis. During pre-dialysis care 9 (6.8%) pa-
tients died. Eighteen (13.7%) patients were lost to follow-
up; 9 (50.0%) of which had a UA level above the median
level. Thirteen (9.9%) patients were still on pre-dialysis
care at the end of follow up (February 12, 2013). Median
follow-up time was 16.4 (IQR 7.7-25.4) and 20.4 (IQR 7.6-
32.3) months for patients with UA levels above the me-
dian and below the median level, respectively. Figure 1
shows the Kaplan-Meier curves for those two patient
groups. Patients showed a higher probability for start-
ing dialysis if UA levels were above the median level at
baseline.
The crude Cox proportional hazards analysis resulted
in a HR for starting dialysis of 1.08 (95% CI 0.94 – 1.24;
p = 0.27) for each mg/dl higher UA level at baseline. Ad-
justment for variables in model 1 resulted in a HR for
starting dialysis of 1.18 (95% CI 1.01 – 1.38; p = 0.041).
Additional adjustment for variables in model 2 increased
the HR for starting dialysis to 1.26 (95% CI 1.06 – 1.49;
p = 0.009) (Table 3).
Sensitivity analyses
Our sensitivity analyses showed robustness of results.
First, results for LMM and Cox proportional hazards ana-
lyses without imputation of missing data were similar to
and in line with the results based on the imputed data.
Second, we dichotomized based on normal UA levels in
men and women. Results did not change for different UA
categories in any of the analyses. Third, adding baseline
eGFR to the multivariable models did not substantially
change results.Table 2 Linear mixed model for the annual rate of decline
in renal function
Mean decline in eGFR
(ml/min/1.73 m2)
−1.61 (95% CI −2.01; −1.22)
Change in decline in eGFR per mg/dl increase in UA at baseline
Crude (n = 129) −0.14 (95% CI −0.61; 0.33)
Adjusted for Model 1 (n = 129) −0.05 (95% CI −0.56; 0.47)
Adjusted for Model 2 (n = 129) −0.14 (95% CI −0.70; 0.42)
Model 1 = Age, sex, ethnicity, PKD, BMI, CVD, hypertension, DM, protein
restricted diet, SBD.
Model 2 = Model 1 + LDL, cholesterol, proteinuria, diuretics, allopurinol.Discussion
Our study investigated the rate of decline in renal function
and time until start of dialysis associated with each mg/dl
higher UA level. Crude analyses showed that each mg/dl
higher UA level was associated with a 1.08-fold higher rate
of starting dialysis. After extensive adjustment for poten-
tial confounding the HR increased to 1.26. Our analyses
showed that UA levels at baseline were not associated with
the rate of decline in renal function.
Uric acid and decline in renal function
Previous animal studies have shown that UA can lead to
glomerular hypertension, elevated renal vascular resist-
ance, reduced renal blood flow [26-28], activation of
renin-angiotensin system (RAS), arteriolosclerosis, glom-
erular hypertrophy, glomerulosclerosis, and interstitial
disease [29,30] by inducing oxidative stress and endothe-
lial dysfunction indicating that UA could contribute to
renal damage.
Several studies have been conducted on the relation
between baseline UA levels and the decline in renal
function, but data in patients with CKD stage IV-V are
limited. Kuo et al. studied the association between hy-
peruricemia and annual decline in eGFR in 63,758 pa-
tients with an initial eGFR ≥ 60 ml/min/1.73 m2 and no
gout in Taiwan [14]. The patients with hyperuricemia
(n = 11,869) had an annual decline of eGFR that was al-
most twice as high as patients with normouricemia, 2.5
vs. 1.3 ml/min/1.73 m2. Bellomo et al. followed 824
healthy people for 5 years and found that UA is an
independent risk factor for GFR decrease [12]. Zhang
et al. also investigated the association between UA
levels and GFR decline in 1,410 healthy participants
with baseline eGFR > 60 ml/min/1.73 m2 in Beijing,
China. Results showed that each mg/dl increase at
baseline is associated with 19% more risk for GFR de-
cline [15]. Obermayr et al. followed 21,475 healthy vol-
unteers for 7 years in order to examine the association
between hyperuricemia and the development of new-
onset kidney disease, which was defined as eGFR < 60
ml/min/1.73 m2. After adjustment, patients in the third
tertile (UA ≥ 9.0 mg/dl) had a 2.49 times higher risk of
developing CKD (stage III; eGFR < 60 ml/min/1.73 m2)
[13]. Weiner et al. performed a similar study in 13,338
participants of the Atherosclerosis Risks in Communi-
ties study or the Cardiovascular Health Study. Those
patients were followed for an average of 8.5 years and
had intact renal function. Adjusted results showed that
each mg/dl increase in UA level led to a 1.07 times
higher risk of getting CKD (stage III; eGFR < 60 ml/
min/1.73 m2) [31]. Sturm et al. studied the association
between UA levels and CKD progression in 177 non-
diabetic CKD patients (stage I-V) that were followed
for seven years. They found that UA was not predictive
Figure 1 Kaplan-Meier for start of dialysis between hyperuricemics versus normouricemics.
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patients using UA lowering drugs all results pointed
towards a faster progression in patients with high levels
of UA [32]. In the MDRD study the associations be-
tween UA at baseline and all-cause mortality, CVD
mortality and kidney failure were studied in CKD stages
III–IV patients. In this study tertiles of UA were not
associated with kidney failure [33].
Except for the last two studies, the patients included
were healthier or had less severe CKD compared with
the patients in our study. These studies demonstrated
an association between UA at baseline and the rate of
decline in renal function, whereas this association was
not present in the last two studies and our study. This
suggests that the effects of UA levels at baseline on the
rate of decline in renal function differ between CKD
stages.
Uric acid and start of dialysis
High UA levels at baseline were associated with a shorter
time until start of dialysis. Since UA was not associatedTable 3 Cox proportional hazards model for time until
start of dialysis
UA per mg/dl increase at baseline
Crude HR (n = 131) 1.08 (95% CI 0.94; 1.24)
Adjusted HR model 1 (n = 131) 1.18 (95% CI 1.00; 1.38)
Adjusted HR model 2 (n = 131) 1.26 (95% CI 1.06; 1.50)
Model 1 = Age, sex, ethnicity, PKD, BMI, CVD, hypertension, DM, protein
restricted diet, SBD.
Model 2 = Model 1 + LDL, cholesterol, proteinuria, diuretics, allopurinol.with decline in renal function in our cohort, this associ-
ation might be explained by clinical symptoms such as
gout that relate to UA accumulation. Gout is caused by
deposition of UA crystals in the joints, most notably in
the metatarsal-interphalangeal joint of the big toe. Pain-
ful and disabling symptoms of gout arthritis could have
contributed to the decision of the nephrologist and pa-
tient to start dialysis. Furthermore, another explanation
could be that high levels of UA might have resulted in
other symptoms or clinical conditions such as renal
stones or hypertension that affect the decision to start
dialysis.Strengths and limitations
A major strength of the PREPARE-2 study is the prospect-
ive longitudinal design in which the course of renal func-
tion can be investigated. However, it has been estimated
that 36-65% of people in the general population with an
eGFR < 15 ml/min/1.73 m2 are not treated by a nephrolo-
gist [34]. While this might hamper the generalizability
of our results to all patients with an eGFR < 15 ml/min/
1.73 m2, our findings can readily be generalized to the
clinical practice of pre-dialysis care. As the majority of our
cohort was Caucasian (94%), our results may be different
in Afro-American, Asian, and other populations.
Our analyses focused on a subset of 131 patients with
a baseline UA measurement. In theory, it is possible that
these 131 patients, which might be considered a limited
size sample, form a selected subgroup. However, we be-
lieve the availability of serum UA levels is independent
of a patient’s rate of decline in renal function or
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believe that our 131 patients form a random sample of
incident patients on pre-dialysis care. Some patients had
missing data for laboratory measurements. We used the
method of multiple imputation to impute these missing
values for each patient, further reducing bias [25].
The PREPARE-2 study is an observational cohort
study, which means that it is possible that patients with
increased UA levels are treated differently because their
physician feels differently about their prognosis. How-
ever, as the effect of UA on the rate of decline in renal
function and time until start of dialysis in this popula-
tion has not been studied before, this is unlikely to have
caused bias. Moreover, in our analyses we adjusted for
known risk factors for an accelerated decline in renal
function and early start of dialysis, further reducing
potential confounding. While other differences in treat-
ment policies, for instance earlier start of dialysis in
more recent years might have occurred, it is most likely
that these were present equally in patients with high
versus low UA levels.
Not unexpectedly, we found patients treated with allo-
purinol had lower UA levels. As we assume allopurinol
had no direct or pleiotropic effects on the rate of decline
in renal function or time until start dialysis, use of allo-
purinol is not considered a potential confounder. This
was confirmed in our analysis, as removing allopurinol
from model 2 showed effects which were not materially
different (data not shown). Moreover, allopurinol is pre-
scribed as preventive treatment in patients with recur-
rent gout, which means that physicians are unlikely to
more easily prescribe allopurinol to patients that they
feel are at risk to start early.
Conclusion
Higher UA levels in incident pre-dialysis patients are a
risk factor for an early start of dialysis, although no asso-
ciation with accelerated decline in renal function was
found. This may indicate that patients with higher UA
levels should be referred earlier to pre-dialysis care in
order to guarantee appropriate preparation for start of
dialysis. In the future UA levels might guide nephrolo-
gists in assessing the optimal moment to start dialysis,
because we have established that higher baseline UA
levels lead to an earlier start of dialysis, independent of
other factors.
Therefore, more research is needed that focuses on the
association between individual patient signs, symptoms,
laboratory values and survival and quality of life on dialy-
sis. This association will be investigated in the European
EQUAL study that can aid nephrologists and patients in
making a more evidence based decision regarding the
need to start dialysis for a specific patient. In the EQUAL
study UA data will be collected.Additional file
Additional file 1: Ethical approval Prepare-2 study.
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